We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394.
- Authors
Qin, Shukui; Fang, Weijia; Ren, Zhenggang; Ou, Shuangyan; Lim, Ho Yeong; Zhang, Feng; Lee, Kin Chung; Choi, Hye Jin; Tong, Jiandong; Tao, Min; Xu, Aibing; Cheng, Ashley; Lu, Chang-Hsien; Chiu, Chang-Fang; Wahid, Mohamed Ibrahim Abdul; Kamble, Shital; Norquist, Josephine M.; Zhong, Wenyan; Li, Chen; Chen, Zhendong
- Abstract
Introduction: KEYNOTE-394 showed pembrolizumab significantly improved overall survival, progression-free survival, and objective response rate with manageable safety versus placebo for patients from Asia with previously treated advanced hepatocellular carcinoma. We present results on health-related quality of life (HRQoL). Methods: HRQoL was evaluated using the EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EuroQol-5D-3L (EQ-5D-3L) questionnaires. Key HRQoL endpoints were least squares mean (LSM) score changes from baseline to week 12 and time to deterioration (TTD) for EORTC QLQ-C30 global health status (GHS)/QoL. p values were one-sided and nominal without adjustment for multiplicity. Results: The HRQoL population included patients randomly assigned to pembrolizumab (n = 298) and placebo (n = 152). From baseline to week 12, a greater decline in EORTC QLQ-C30 GHS/QoL score was observed with placebo (LSM, −8.4; 95% CI: −11.7 to −5.1) versus pembrolizumab (−4.0; 95% CI: −6.4 to −1.6; difference vs. placebo: 4.4; 95% CI: 0.5–8.4; nominal p = 0.0142). Similarly, a greater decline in the EQ-5D-3L visual analog scale score was observed with placebo (−6.9; 95% CI: −9.4 to −4.5) versus pembrolizumab (−2.7; 95% CI: −4.5 to −1.0; difference vs. placebo: 4.2; 95% CI: 1.2–7.2; nominal p = 0.0030). TTD in EORTC QLQ-C30 GHS/QoL score was similar between arms (hazard ratio, 0.85; 95% CI: 0.58–1.25; nominal p = 0.1993). Conclusion: Patients receiving placebo showed a greater decline in HRQoL than those receiving pembrolizumab. Combined with efficacy and safety data from KEYNOTE-394 and the global KEYNOTE-240 and KEYNOTE-224 trials, our data support the clinically meaningful benefit and manageable tolerability of pembrolizumab as second-line therapy for patients with advanced hepatocellular carcinoma.
- Subjects
QUALITY of life; VISUAL analog scale; PATIENT reported outcome measures; HEPATOCELLULAR carcinoma; OVERALL survival
- Publication
Liver Cancer (2235-1795), 2024, Vol 13, Issue 4, p389
- ISSN
2235-1795
- Publication type
Article
- DOI
10.1159/000535338